DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia. 2022

Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu, People's Republic of China.

Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes gave been explored in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a total of 1532 AML patients from three GEO databases were included, five genes with potential prognostic value (DLC1, NF1B, DENND5B, TANC2 and ELAVL4) were screened by weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE). Based on this, we conducted survival analysis of the above five genes through the TCGA database and found that low level of DLC1 was detrimental to the long-term prognosis of AML patients. We also performed external validation in 48 AML patients from our medical center to analyze the impact of DLC1 level on prognosis. In conclusion, DLC1 may be a potential marker affecting the prognosis of AML, and its deficiency is associated with poor prognosis.

UI MeSH Term Description Entries

Related Publications

Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2018, Cancer biomarkers : section A of Disease markers,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2021, Cancer biomarkers : section A of Disease markers,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2021, Frontiers in molecular biosciences,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
May 2019, Journal of translational medicine,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2020, Frontiers in oncology,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2020, Therapeutic advances in hematology,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
June 2020, Clinical laboratory,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
April 2016, Japanese journal of clinical oncology,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
January 2021, Technology in cancer research & treatment,
Xueqian Li, and Jiaqian Qi, and Xiaofei Song, and Xiaoyan Xu, and Tingting Pan, and Hong Wang, and Jingyi Yang, and Yue Han
September 2017, Experimental hematology,
Copied contents to your clipboard!